全部分类
  • Mosapride Citrate
Mosapride Citrate的可视化放大

Mosapride Citrate

A 5-HT4 receptor agonist

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

Mosapride Citrate的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 5mg
    ¥437.00
    350.00
    - +
  • 25mg
    ¥625.00
    500.00
    - +
  • 100mg
    ¥1387.00
    1110.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajci19314
  • CAS: 112885-42-4
  • 别名: 莫沙必利柠檬酸盐; TAK-370 citrate; AS-4370 citrate
  • 分子式: C21H25ClFN3O3.C6H8O7
  • 分子量: 614.02
  • 纯度: >98%
  • 溶解度: ≥ 30.701mg/mL in DMSO
  • 储存: Store at -20°C
  • 库存: 现货

Background

Mosapride citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist.Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhoea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000 - 3,000 times the therapeutic dose to elicit cardiovascular effects.


参考文献:
[1]. Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.
[2]. Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91.
[3]. Odaka T, et al. Serotonin 5- HT4 receptor agonist (mosapride citrate). Nihon Rinsho. 2006 Aug;64(8):1491-4.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算